Addiction (Abingdon, England)
July 1, 2026
Daniel T. Myran, Rachael MacDonald-Spracklin, Alexander R Levesque et al.
Recent increasing interest in hallucinogens has underscored the critical gaps in our understanding of their adverse health effects and healthcare usage over time. The current study aimed to examine changes in emergency department (ED) visit rates involving hallucinogens, clinical outcomes of visits and the characteristics of individuals with ED visits involving hallucinogens. Repeated...
Canadian Journal of Public Health
March 19, 2026
Jenna Matsukubo, Erik Loewen Friesen, Rachael MacDonald-Spracklin et al.
1 citation
IntroductionThe use of psychedelics has increased in Canada in recent years. Although non-medical psilocybin use is prohibited under the Controlled Drugs and Substances Act, we previously documented the emergence of grey-market brick-and-mortar psilocybin retailers. This study examined changes in the number, composition, and geographic distribution of Canadian psilocybin retail stores between...
PLoS Medicine
December 1, 2025
Daniel T. Myran, Rachael MacDonald-Spracklin, Michael Pugliese et al.
Hallucinogen use for both recreational and medical purposes is rapidly increasing globally, raising concerns about potential adverse effects. This study examined the risk of incident mania or bipolar disorder (BD) diagnosis associated with having an emergency department (ED) visit or hospitalization involving hallucinogens. We used a population-based cohort study of all individuals aged 14-65...
Eur Neuropsychopharmacol
November 7, 2025
Mikkel Højlund, Helin Y. Kafali, Begüm Kırmızı et al.
12 citations
Efficacy, all-cause discontinuation, and safety of serotonergic psychedelics and MDMA to treat mental disorders: A living systematic review with meta-analysis.
Therapeutic Advances in Psychopharmacology
September 1, 2025
Stanley Wong, Gray Meckling, Nicholas Fabiano et al.
6 citations
Background: Suicidal ideation, attempts, and deaths present a major and tragic public health concern. Recent trials of psilocybin therapy (PT) have shown promise in treating treatment-resistant depression and have found a reduction in suicidal ideation. Given the growth of PT research, there is a need to further understand its effect on suicidal ideation, attempts, and deaths. Objective: To...
JAMA Network Open
April 1, 2025
Jenna Matsukubo, Sarah Dickson, Jennifer Xiao et al.
7 citations
Importance There is growing societal interest in and use of psilocybin. While psilocybin in Canada is illegal outside of clinical trials, there have been anecdotal reports of increasing access via unregulated online purchases and retail dispensaries. Objective To describe access to and the characteristics of psilocybin dispensaries across Canada and the health claims and warnings made on...
CMAJ
March 2, 2025
Daniel T. Myran, Jennifer Xiao, Nicholas Fabiano et al.
8 citations
Background: Although clinical trials involving psychedelic-assisted psychotherapy have not observed short-term increases in the risk of death, limited data exist on mortality associated with hallucinogen use outside of controlled trial settings. We sought to determine whether people with an emergency department visit or hospital admission involving hallucinogen use were at increased risk of...
JAMA Psychiatry
February 1, 2025
Daniel T. Myran, Michael Pugliese, Jennifer Xiao et al.
23 citations
Interest in and use of hallucinogens has been increasing rapidly. While a frequently raised concern is that hallucinogens may be associated with an increased risk of psychosis, there are limited data on this association. To examine whether individuals with an emergency department (ED) visit involving hallucinogen use have an increased risk of developing a schizophrenia spectrum disorder (SSD)....
JAMA Network Open
February 1, 2025
D. Myran, Michael Pugliese, Lyndsay D. Harrison et al.
Key Points Question Were the liberalization of medical cannabis and the legalization of nonmedical cannabis in Canada associated with changes in the population-attributable fraction of cannabis use disorders associated with schizophrenia? Findings In this population-based cohort study comprising 13 588 681 individuals, the population-attributable fraction of cannabis use disorder associated...